Latest filing published 27 Apr 2026 for Amicus Therapeutics, INC., €1.2M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Margaret G. Mcglynn (senior executive) discloses dealings in 3 companies, chiefly Amicus Therapeutics, Inc., Vertex Pharmaceuticals INC / MA and Novavax Inc. Between 1 May 2021 and 27 April 2026, the trades on record add up to 22 filings.
On the market, this insider has only sold: 1 sale, €180k in total. The rest of the record consists of 7 share grants and 11 option exercises.
On 27 April 2026 came the latest disclosure, a transaction for €1.2M in Amicus Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations